ArticleJournal of fungi (Basel, Switzerland)2017
MIC Distributions and Evaluation of Fungicidal Activity for Amphotericin B, Itraconazole, Voriconazole, Posaconazole and Caspofungin and 20 Species of Pathogenic Filamentous Fungi Determined Using the CLSI Broth Microdilution Method.
Article in Journal of fungi (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Establishment of epidemiological cutoff values againstJournal of clinical microbiology · 2026Article
- Preliminary Evaluation of Gemini-Surfactant-Based Formulations for Antifungal Seed Treatment in Wheat.Molecules (Basel, Switzerland) · 2026Article
- Leaf mold extract agar facilitates recovery of soil bacterial diversity beyond Bacillus dominance.Applied microbiology and biotechnology · 2026Article
- Antimicrobial activity and antifungal mechanistic study of 3‑substituted oxindoles against Aspergillus niger.Scientific reports · 2025Article
- Evaluation of the combined efficacy of inhibitors of heat shock protein 90 and calcineurin with commonly used antifungals againstCurrent medical mycology · 2025Article
- A human-relevant alternative infection model for mucormycosis using the silkworm Bombyx mori.PloS one · 2025Article
- First case of invasiveMedical mycology case reports · 2024Article
- Does sorghum phenolic extract have antifungal effect?Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Cryptophytes as potential source of natural antimicrobials for food preservation.Frontiers in microbiology · 2024Article
- Changes in fungal taxonomy: mycological rationale and clinical implications.Clinical microbiology reviews · 2023Review
- Citizen science reveals landscape-scale exposures to multiazole-resistantScience advances · 2023Article
- Article
- Mucormycosis and COVID-19-Associated Mucormycosis: Insights of a Deadly but Neglected Mycosis.Journal of fungi (Basel, Switzerland) · 2022Review
- Article
- Antifungal activity of Taurolidine against Mucorales: An in vitro study on clinical isolates.Current medical mycology · 2022Article
- Recent Advances and Future Directions in the Understanding of Mucormycosis.Frontiers in cellular and infection microbiology · 2022Review
- Disseminated Rasamsonia argillacea species complex infections in 8 dogs.Journal of veterinary internal medicine · 2021Article
- First Report of a Case of Ocular Infection Caused byPathogens (Basel, Switzerland) · 2021Article
- Physiological Responses of Aspergillus niger Challenged with Itraconazole.Antimicrobial agents and chemotherapy · 2021Article
- In Vitro Antifungal Drug Resistance Profiles of Clinically Relevant Members of the Mucorales (Mucoromycota) Especially with the Newer Triazoles.Journal of fungi (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For filamentous fungi (moulds), species-specific interpretive breakpoints and epidemiological cut-off values (ECVs) have only been proposed for a limited number of fungal species-antifungal agent combinations, with the result that clinical breakpoints are lacking for most emerging mould pathogens. In the current study, we have compiled minimum inhibitory concentration (MIC) data for 4869 clinical mould isolates and present full MIC distributions for amphotericin B, itraconazole, voriconazole, posaconazole, and caspofungin with these isolates which comprise 20 species/genera. In addition, we present the results of an assessment of the fungicidal activity of these same five antifungal agents against a panel of 123 mould isolates comprising 16 of the same species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.